Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs Transcript - Thomson StreetEvents

Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs Transcript

Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs Transcript - Thomson StreetEvents
Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs Transcript
Published Feb 04, 2013
Published Feb 04, 2013
Price $54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of IDIX conference call or presentation 4-Feb-13 9:30pm GMT

  
Report Type:

Transcript

Source:
Company:
Ticker
Time
9:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Katherine Xu - William Blair & Co. - Analyst : Good afternoon. I am just wondering what did the FDA say -- you cited -- let's say what did they cite as a reason for not removing the holds? It's just not enough data or they just don't feel comfortable or -- they need the six and 12 months echoes? What exactly did they --?


Question: Katherine Xu - William Blair & Co. - Analyst : Right, and apparently you guys have accumulated a lot of experience with regards to preclinical safety and how predictive they are to the clinic based on your -- the clinical holds and development over the past few years. I'm just wondering for the upcoming uridine-based nuke, looking at the profile so far, how predictive do you think the clinical safety that you observed so far with that compound would be to reflect the clinical safety? companies. FEBRUARY 04, 2013 / 9:30PM, IDIX - Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs


Question: Katherine Xu - William Blair & Co. - Analyst : Thank you.


Question: Alethia Young - Deutsche Bank - Analyst : Thanks for taking my questions. One is just kind of I wanted to get a little to feel around kind of what are the lessons that you kind of learned from the hold that could be leveraged for the uridine program? Also I just wanted to get your thoughts on like I know the FDA kind of is moving somewhat conservatively with a lot of early-stage nuke programs but can you just kind of talk about how you might -- like have you had any experience with them over the past year or so that may help with those timelines?


Question: Alethia Young - Deutsche Bank - Analyst : And can I ask one quick follow-up? Are the guys, are the people at the FDA you are working with similar or different than like when you moved forward in the preclinical program? Just trying to see if there's any overlap in kind of the staff there or if you can disclose that?


Question: Alethia Young - Deutsche Bank - Analyst : That's very helpful, thanks.


Question: Heather Behanna - JMP Securities - Analyst : Thanks for taking my question. I think most of my questions have already been answered. Just if you can give any color if the prodrug strategies, I know you have looked at a lot of them, but if you -- if the uridine nuke is in the same class as 184 or if you're bringing a new prodrug strategy forward?


Question: Heather Behanna - JMP Securities - Analyst : Great, thank you. companies. FEBRUARY 04, 2013 / 9:30PM, IDIX - Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs


Question: Ying Huang - Barclays Capital - Analyst : Thanks for taking my questions as well. I kind of like have a philosophical question here, maybe for Ron. Given where Gilead is in terms of (inaudible) development, they just unveiled the Phase III data this morning and they've given -- there's another new from Vertex Pharmaceuticals in Phase II. How many news do you think the markets can accommodate? And I was wondering do you think your emphasis going forward will be discovering new news nukes or probably putting more money behind (inaudible) and trying to monetize that asset? Thanks.


Question: Ying Huang - Barclays Capital - Analyst : Thank you.


Question: David Friedman - Morgan Stanley - Analyst : Thanks for taking the question. Just on the collaboration with JNJ, can you just -- I know you guys have laid out some initial timelines in the press release that announced that. But can you give any updated timelines about A, whether there's going to be any enrollment sort of pacing issues like we've seen with the nukes or whether since this is a non-nuke regimen there is -- it's just go as fast as you can? And then given that you guys are in control of the trial, will we be seeing RVR data at some point either by the end of the year or otherwise?


Question: David Friedman - Morgan Stanley - Analyst : Great, so is it possible -- just as a quick follow-up, that we would -- that you guys would show the first 30-patient data as a sort of little mini data set or is that just going to be held until the full trial enrolls?


Question: David Friedman - Morgan Stanley - Analyst : All right, thanks very much.

Table Of Contents

Idenix Pharmaceuticals, Inc. at Oppenheimer Healthcare Conference Transcript – 2013-12-10 – $54.00 – Edited Transcript of IDIX presentation 10-Dec-13 9:30pm GMT

Idenix Pharmaceuticals, Inc. at Deutsche Bank BioFEST Conference (Fireside Chat) Transcript – 2013-12-02 – $54.00 – Edited Transcript of IDIX presentation 2-Dec-13 3:45pm GMT

Idenix Pharmaceuticals, Inc. Q3 2013 Earnings Conference Call Transcript – 2013-10-30 – $54.00 – Edited Transcript of IDIX earnings conference call or presentation 30-Oct-13 8:30pm GMT

Idenix Pharmaceuticals, Inc. Q2 2013 Earnings Conference Call Transcript – 2013-08-07 – $54.00 – Edited Transcript of IDIX earnings conference call or presentation 7-Aug-13 12:00pm GMT

Idenix Pharmaceuticals Inc. Corporate Conference Call To "Provides" Update on Patent Interference Transcript – 2013-03-25 – $54.00 – Edited Transcript of IDIX conference call or presentation 25-Mar-13 12:00pm GMT

Idenix Pharmaceuticals, Inc. at JPMorgan Global Healthcare Conference Transcript – 2013-01-09 – $54.00 – Edited Transcript of IDIX presentation 9-Jan-13 10:00pm GMT

Idenix Pharmaceuticals, Inc. at Oppenheimer Holdings Inc Healthcare Conference Transcript – 2012-12-12 – $54.00 – Edited Transcript of IDIX presentation 12-Dec-12 7:45pm GMT

Idenix Pharmaceuticals, Inc. Q3 2012 Earnings Conference Call and HCV Program Update Transcript – 2012-11-01 – $54.00 – Edited Transcript of IDIX earnings conference call or presentation 1-Nov-12 8:30pm GMT

Idenix Pharmaceuticals, Inc. at UBS Global Life Sciences Conference Transcript – 2012-09-20 – $54.00 – Edited Transcript of IDIX presentation 20-Sep-12 3:00pm GMT

Idenix Pharmaceuticals, Inc. at Morgan Stanley Healthcare Conference Transcript – 2012-09-10 – $54.00 – Edited Transcript of IDIX presentation 10-Sep-12 5:15pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs Transcript" Feb 04, 2013. Alacra Store. Aug 30, 2014. <http://www.alacrastore.com/thomson-streetevents-transcripts/Idenix-Pharmaceuticals-Inc-Holds-Conference-Call-to-Update-on-IDX184-and-IDX19368-Development-Programs-T5005086>
  
APA:
Thomson StreetEvents. (2013). Idenix Pharmaceuticals, Inc. Holds Conference Call to Update on IDX184 and IDX19368 Development Programs Transcript Feb 04, 2013. New York, NY: Alacra Store. Retrieved Aug 30, 2014 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Idenix-Pharmaceuticals-Inc-Holds-Conference-Call-to-Update-on-IDX184-and-IDX19368-Development-Programs-T5005086>
  
$54.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.